INTRODUCTION
The transrectal ultrasound (TRUS)-guided prostate biopsy led diagnostic pathway remains commonplace. However, this leads to misclassification of disease in men at a risk of prostate cancer. 1 Under-sampling of the anterior gland and the deployment of the needle blind to the location of the lesion can potentially miss clinically significant disease while also failing to directly hit the highest grade disease. 1 In addition, this pathway can also result in overdiagnosis and overtreatment. 2 The primary issue is the limited ability of this pathway to discriminate between whether cancer is present and whether it is clinically significant or insignificant. Indeed, the PROMIS study demonstrated that the sensitivity of TRUS to detect clinically significant cancer was quite low. 3 Furthermore, there is a significant risk of systemic sepsis following TRUS biopsy and this is increasing alongside a rise in antimicrobial resistant coliforms. 4 Despite this, the TRUS biopsy still remains the first-line diagnostic test in prostate cancer. 5 The diagnostic pathway requires improvement. Two separate diagnostic innovations may address the need for improved accuracy and safety. First, the implementation of a pre-biopsy multiparametric magnetic resonance imaging (mpMRI) can facilitate targeted sampling of a suspicious area with the potential of reduced number of cores while improving the detection rates of significant disease. 6 Targeted biopsies may be equally good as a template approach in detecting clinically significant disease. 7 Second, the prostate may be approached transperineally rather than via the rectum, easing access to all areas of the prostate, and conferring sepsis rates of less than 0.5%. 8 Transperineal biopsies are often applied in a mapping or zonal technique, sampling the whole gland with a fixed sampling frame of 5-10 mm. This method has demonstrable diagnostic accuracy when compared with the reference standard of radical prostatectomy. 9 However, barriers to widespread adoption include the necessity of general or spinal anaesthetic; operating room time; pathology resources/costs and increased risks of urinary retention, haematuria, haematospermia and temporary erectile dysfunction. Despite this, the approach has gained considerable momentum in the last decade.
Nonetheless, reductions to these burdens are needed to facilitate widespread dissemination of a transperineal approach to prostate biopsy, capitalizing on reduced sepsis rates.
The optimal biopsy strategy might have the following elements. First, it should be mpMRI-led and suspicious areas undergo a targeted biopsy. Second, a transperineal approach should be used to capitalize on significantly reduced sepsis rates and improved gland sampling. Last, these biopsies should be conducted under local anaesthetic. In this study, our objective was to determine the feasibility, tolerability and detection rates using such a pathway.
MATERIALS AND METHODS
In this retrospective study, which was part of a clinical service innovation approved by the institution and receiving research ethics committee exemption, consecutive treatment naive men whose pre-biopsy mpMRI showed a visible lesion and underwent a local anaesthetic transperineal targeted prostate biopsy were included.
MpMRI acquisition was performed according to the European guidelines of Uro-radiology at a single referral centre. 6, 7, 10 Each mpMRI was performed by either a 1.5 or 3.0 Tesla and consisted of T1, T2, diffusionweighted and dynamic contrast (gadolinium)-enhanced sequences. Each scan was reported by one of six experienced, uro-radiologists as previously described. 11 Lesions were scored using a Likert-like scale of 1-5. 12 Lesions scoring 3 ( Figure 1) were indeterminate, and those scoring 4 ( Figure 2 ) or 5 ( Figure 3 ) were thought 'likely' or 'highly likely' to contain a malignant lesion, which was either ⩾ 0.2 ml in volume and/or had high-grade components within (Gleason ⩾ 3+4). 13 The Likert scoring system, like the better-known PI-RADs scoring system also uses a five-point score. However, as a complement to the strict criteria of PI-RADs, Likert allows for the overall impression of the radiologist in their reflection of the mpMRI images. Regardless, equivalence of the two scoring systems has been demonstrated. 14 Biopsies were performed by 12 urologists of varying years of experience in transperineal mapping but all assessed as competent and expert in targeted biopsies. All were performed in a non-operating theatre procedure room as ambulatory day cases, with one urologist and two nursing assistants. One hour before biopsy, the men received oral analgesia (tramadol 100 mg) and topical 2% diltiazem ointment to relax the anal sphincter. They were placed in the lithotomy position and given a single dose of intramuscular antibiotics (gentamicin 80 mg) as per the local antimicrobial policy. The scrotum was supported with adhesive tape with the scrotal skin protected by non-adhesive dressings. Twenty millilitres of lidocaine infused gel (Instillagel) was inserted into the rectum and applied to the anus to aid toleration of the ultrasound probe. After two minutes, a bi-planer 7.5 MHz ultrasound transducer was inserted transrectally. The perineum was then cleaned with Chloraprep and 20 ml of 0.5% bupivacaine with adrenaline (1 in 200 000) was infiltrated in the perineal skin just anterior to the anus as well as deep into subcutaneous tissue. After 2 min, a peri-prostatic block was performed transperineally by infiltration of the peri-prostatic nerves with a mixture of 0.5% bupivacaine 10 ml and 1% lidocaine 10 ml ( Figure 4) . Finally, the probe was attached to a brachytherapy stepper and cradle. A minimum of four transperineal targeted biopsy cores were taken using visual estimation (or cognitive biopsies), via a standard brachytherapy grid and guided by evaluating the mpMRI images and a pictorial diagrammatic report provided by the uro-radiologist. Only lesions seen on the mpMRI were targeted.
In the first 20 patients, visual analogue pain scores (VAS) and the length of procedures were collected to determine tolerability. This is a continuous scale anchored by the descriptors 'no pain' and 'worst pain possible', with 0 and 10 corresponding to the former and latter respectively. Overall cancer detection rates were determined as was the rates of detection for measures of clinically significant disease using a number of thresholds. Postoperative questionnaires ( Figure 5 ) were sent to each man after their biopsies.
The definition of disease according to the University College London (UCL) criteria for clinical significance developed for transperineal biopsies were used 15 as they have been validated for transperineal, sagittal plane approaches to the prostate via a 5 mm brachytherapy template. 15 Definition 1 was the presence of Gleason ⩾ 4+3 and/or maximum cancer core length ⩾ 6mm and definition 2 was the presence of Gleason ⩾ 3+4 and/or maximum cancer core length ⩾ 4mm. The detection rate of lesions containing Gleason pattern 4 alone regardless of cancer core length were considered separately. Epstein criteria were not used, as these were developed for TRUS biopsy where the sampling technique is random, tangential and have not been validated on transperineal biopsies. 16 Differences in cancer detection rates by Likert score were compared for significance using the Chi-squared test (Po0.05).
In addition, the group was separated into men presenting with a PSA ⩾ 10 ng ml − 1 and o10 ng ml − 1 . Differences between these groups were evaluated for prostate volume (Student's t-test (Po0.05)) and lesion volume (one-way analysis of variance (Po0.05)). PSA-dependent differences in the attributable Likert score on mpMRI were compared (Chisquared test (P o0.05)). Statistical analysis was conducted using SPSS version 22 (IBM Released 2013. IBM SPSS Statistics for Windows, Version 22.0. Armonk, NY, USA).
Complications were assessed for by adverse event reporting at follow-up appointments within 2 weeks.
RESULTS

Baseline demographics
Between September 2013 and January 2016, 181 consecutive treatment naive men with 243 lesions on mpMRI underwent targeted prostate biopsy under local anaesthetic (Table 1a) . Mean age at the time of biopsy was 68 (range 46 to 92). A total 111 (61%) were primary biopsy, 24 (13%) had undergone previous negative TRUS biopsy, 33 (18%) underwent restratification following TRUS biopsy and 13 (7%) underwent biopsy as part of active surveillance.
Median PSA was 11.0 ng ml − 1 (interquartile range (IQR): 6.0-22.0 ng ml − 1 ). Median prostate volume was 46 ml (IQR: 34-63 ml). Median target lesion volume was 0.65 ml (IQR: 0.3-2.1 ml). One hundred thirty-eight men had a single targeted lesion, 31 had two, 13 had three and 1 had four. Of the 243 lesions targeted, 62 (26%) scored 3 on the radiological Likert-like scale, 87 (36%) scored 4 and 94 (39%) scored 5. A median of five (IQR: 4-6) cores were taken per lesion.
Primary outcomes Tolerability and adverse events. There were no episodes of sepsis and none had bleeding requiring catheterization. A single man Reporting on a novel biopsy technique EJ Bass et al developed acute urinary retention. There were no admissions following discharge. The first 20 men were assessed by the VAS for pain to assess for tolerability. The median intraoperative score was 1.0 (IQR: 0.0-2.4). Mean and median procedure lengths were 27 and 30 min, respectively. One procedure was abandoned due to patient discomfort. Seventy-five men responded to their questionnaires. Sixty-seven men (89%) were not dissatisfied with their biopsy and 67 (89%) would recommend one to others. 
Secondary outcomes
Overall cancer detection. Prostate cancer was detected in 142/181 (78%). When analysed by lesion (Table 2a) , 180/243 (74%) had prostate cancer detected. Overall, the median number of positive cores for each lesion was 3 (IQR: 2-4). The maximum cancer core length involvement was median 7 mm (IQR: 3 mm to 10 mm).
Detection rates by radiology score. These are demonstrated in Table 2b . In all scenarios, namely any cancer detected, UCL definition 1 and 2 and any Gleason 4 disease detected, there was a statistically significant correlation with higher Likert scores (Chi-squared test, P o 0.00001).
Cancer detection by PSA. PSA demographics and their respective detection rates are demonstrated in Table 1b . Men presenting with a PSA ⩾ 10 ng ml − 1 also had significantly larger lesions (one-way analysis of variance, P o 0.001).
The Likert scores attributed to identified lesions in each group are demonstrated in Table 1b . Men with higher PSA levels were more likely to have higher scoring lesions on mpMRI (Chi-squared, Po 0.00001).
Clinically significant disease (UCL definitions 1 and 2) was found in 65 (55%) of lesions in men presenting with a PSA o10 ng ml . These differences were statistically significant (Chi-squared, P = 0.00006).
DISCUSSION
In summary, to the best of our knowledge, this is the first time that local anaesthetic transperineal mpMRI-targeted cognitive prostate biopsy has been reported. We have shown that this technique is feasible, acceptable, tolerable by patients, learned with relative ease, has very minimal adverse events and no sepsis. It also seems to be highly accurate in detecting clinically significant cancer with 96% of men scoring 4 or 5 on mpMRI harbouring Gleason pattern 4 disease. Limitations First, some argue that targeted biopsies alone without sampling of normal-appearing gland on mpMRI risks missing significant disease. Our change in strategy for this group of men occurred after our paired analyses of mpMRI versus transperineal template mapping biopsies in men demonstrated that mpMRI visually directed biopsies were equivalent in detection rate to full mapping biopsies when both were conducted in the same men under general anaesthetic. 17 This has been supported by other 18 Other authors have also demonstrated negative predictive values of 90% or higher. [19] [20] [21] Second, consensus is lacking regarding the definition of clinically significant cancer. Therefore, we used a number of definitions to incorporate professional uncertainty. Third, multiple radiologists and urologists were involved in the reporting of mpMRI scans and biopsies although this enforces the internal validity of our findings and likely reflects the clinical reality of wider practice. Fourth, the return rate of questionnaires (75/181) is low and this may introduce a degree of nonresponse bias.
Clinical implications
The diagnosis and subsequent management of prostate cancer is still driven by TRUS biopsy despite its accepted inaccuracy. Indeed, the original six-core TRUS biopsy technique was described as random systematic by Stamey in 1989. 22 Subsequently, the procedure was expanded to a 10-to 12-core technique over time. This was somewhat successful in increasing the negative predictive value of TRUS biopsy. However, it also led to the detection of increased numbers of low-risk disease. Histological studies have demonstrated this is present in more than 40% of men over the age of 50. 23 Furthermore, the TRUS biopsy is poor at detecting disease in anterior and apical aspects of the gland leading to misclassification of disease that is upgraded at prostatectomy. 24 Owing to these concerns, transperineal mapping biopsy is becoming more popular. However, concerns regarding its cost, the need for general anaesthetic and increased complications in the form of haematuria, haematospermia and urinary retention are likely to have prevented its wider dissemination. With the advent of mpMRI, which has shown high levels of accuracy for the detection of clinically significant cancer when compared with whole-mount histological specimens 25 and transperineal mapping biopsies, 17 we can now contemplate the prospect of a wholly noninvasive diagnostic tool for prostate cancer. For example, the results of the PROMIS trial demonstrate the sensitivity and negative predictive value of mpMRI in detecting clinically significant disease as 93% and 89%, respectively. 3 Clearly, an image-guided approach to prostate biopsy in line with current practice in other solid-organ malignancies can now be contemplated. 26 Naturally, there is concern regarding not sampling normal areas with normal mpMRI appearances. However, numerous centres have reported their experiences with mpMRI-targeted biopsy when compared with systematic biopsy strategies, demonstrating equivalent or improved cancer detection rates, 6, 7, 27 improvements in biopsy efficiency 5 and reductions in missed diagnoses of significant cancer. 28 Our own series of 535 men who underwent both visually estimated mpMRI-targeted biopsy and systematic transperineal biopsies showed clinically significant cancer detection rates of 40% and 47%, respectively. 29 Furthermore, the PROMIS study 3 has shown that the negative predictive value of mpMRI is excellent when template biopsies were used as the reference standard. Finally, the publication of the PROTECT study 30 -which showed no 10-year cancer-specific survival benefit between radical prostatectomy, radical radiotherapy or active surveillance. This exemplified the problem of overdiagnosis from systematic biopsies, albeit in the form of TRUS.
In addition, some centres have described their use of transperineal biopsy (non-targeted) under local anaesthetic with encouraging results. [31] [32] [33] [34] Novella et al. 31 compared the procedure with 102 consecutive patients. Only 11 (15.3%) reported intraoperative pain levels of moderate or higher. 31 Kubo et al.
32
compared intraoperative pain levels in 45 patients who underwent both 12-core TRUS biopsy and 14-core transperineal biopsy solely under local anaesthetic. The median VAS score was 2.67 for TRUS and 2.93 for transperineal biopsy with no significant difference demonstrated. 32 Iremashvili et al. 33 reported a randomized clinical trial where 150 patients underwent 12-core transperineal prostate biopsy under local anaesthesia, some with a pudendal nerve block. Those who received a pudendal nerve block did experience less intraoperative pain at a median of 1.83 on VAS. 33 However, even without this, the median VAS suggested mild intraoperative pain levels at a median of 2.41. 33 Most recently, Smith et al. 34 described a series of 50 consecutive patients that underwent sector transperineal biopsies solely under local anaesthetic. Only two (4%) men reported that they would not undergo the same procedure again. 34 Although the use of transperineal template mapping biopsies has shown a significant growth in use due to its highly accurate detection and risk stratification of disease, it has met with criticism due to its healthcare and patient burden. For the one million men who have a TRUS biopsy in USA or Europe each year to undergo template mapping biopsies would be unsustainable. MpMRI has shown performance characteristics in high volume experienced centres that make it a viable alternative to TRUS and template biopsies. As a result, many centres have adopted mpMRI-targeted biopsies. However, much of this still relies on traversing the rectum. Transperineal MRI/ultrasound fusion biopsy devices existing have yet to prove their superiority over visually estimated biopsies. This effect may be due to the relatively fixed position of the prostate in relation to the brachytherapy grid when it is locked in direct contact with the perineum. The largest such comparative trial-PROFUS-by Wysock et al. 35 did not demonstrate a significant difference in cancer detection rate between visually estimated and MRI/ultrasound fusion techniques. Furthermore, a recent systematic review showed no discernable difference between visual/cognitive targeting and image fusion as the ranges of detection overlapped significantly between the two forms. 36 Our strategy to combine the key elements of an optimal diagnostic pathway may facilitate the wider adoption of transperineal prostate biopsy, which is known to have minimal risk of sepsis while retaining diagnostic accuracy.
Local anaesthetic, transperineal visual estimated mpMRItargeted prostate biopsy is a novel approach that is feasible, tolerable, can be performed in an ambulatory setting and does not have a steep learning curve. It carries high levels of cancer detection and may offer a sustainable and legitimate alternative to transrectal biopsies. Further analysis demonstrating both the technique's clinical efficacy and a beneficial health economic impact would be a robust addition to the evidence base and advance its wider use. In particular, comparative data demonstrating superiority against current standards of care are welcomed and trials are currently ongoing.
